Nautilus Biotechnology, Inc.

A development-stage biotechnology company, Nautilus Biotechnology develops proteomics platform technology designed to quantify and analyze protein complexity in biological samples. The company's core offering, the Nautilus Platform, provides an integrated end-to-end solution combining specialized instruments, consumables, and software analysis tools. The system employs high-resolution optical imaging with integrated fluidics and liquid handling capabilities to deposit protein libraries onto flow cells and execute rapid multi-cycle analysis runs that decode and quantify proteins in samples.

The company's product portfolio includes a proteome analysis system, reagent kits containing sample preparation materials, flow cells, multi-affinity probe reagents, and instrument buffer systems required for multi-cycle analysis operations. Revenue is generated through instrument sales, consumables, and associated software offerings. Nautilus maintains research collaborations focused on disease applications, including work with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation investigating alpha-synuclein protein connections to Parkinson's disease.

Nautilus operates with approximately 124 full-time employees and is headquartered in Seattle, Washington. The company was established in 2016 and trades on Nasdaq. As a development-stage enterprise, the company continues to advance its platform technology toward broader commercial deployment.